High-throughput screening (HTS) and hit validation to identify small molecule inhibitors with activity against NS3/4A proteases from multiple hepatitis C virus genotypes.

Development of drug-resistant mutations has been a major problem with all currently developed Hepatitis C Virus (HCV) NS3/4A inhibitors, including the two FDA approved drugs, significantly reducing the efficacy of these inhibitors. The high incidence of drug-resistance mutations and the limited util...

Full description

Bibliographic Details
Main Authors: Hyun Lee, Tian Zhu, Kavankumar Patel, Yan-Yan Zhang, Lena Truong, Kirk E Hevener, Joseph L Gatuz, Gitanjali Subramanya, Hyun-Young Jeong, Susan L Uprichard, Michael E Johnson
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3793977?pdf=render